The Cooper Companies Inc
COO
$81.40 5.67%
Exchange: NASDAQ | Sector: Healthcare | Industry: Medical Instruments Supplies
Q2 2024
Published: May 31, 2024

Earnings Highlights

  • Revenue of $942.60M up 7.4% year-over-year
  • EPS of $0.44 increased by 125% from previous year
  • Gross margin of 61.6%
  • Net income of 88.90M
  • ""We are planning to raise our revenue and earnings guidance by incorporating this past quarter and the momentum we're seeing in our markets." - Al White" - Al White
COO
The Cooper Companies Inc

Executive Summary

The Cooper Companies Inc reported exceptional results for Q2 2024, achieving record quarterly revenues of $943 million, representing an 8% increase year-over-year. This growth was primarily driven by CooperVision, which returned to double-digit growth with an 11% increase in revenue. CooperSurgical, despite operational challenges related to a systems upgrade, managed a respectable 4% revenue growth. Management highlights include successful expansion in the silicone hydrogel lens portfolio and strategic investments that are beginning to bear fruit, with a focus on increased production capacity amidst robust market demand. Looking ahead, management has raised guidance for both revenue and earnings as they capitalize on operational momentum and innovative product offerings.

Key Performance Indicators

Revenue
Increasing
942.60M
QoQ: 1.18% | YoY: 7.43%
Gross Profit
Decreasing
580.90M
61.63% margin
QoQ: 1.29% | YoY: -0.34%
Operating Income
Increasing
161.70M
QoQ: 5.62% | YoY: 67.91%
Net Income
Increasing
88.90M
QoQ: 9.48% | YoY: 123.37%
EPS
Increasing
0.45
QoQ: 9.76% | YoY: 125.00%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 1,002.30 0.44 +6.3% View
Q1 2025 964.70 0.52 +3.6% View
Q4 2024 1,018.40 0.58 +9.9% View
Q3 2024 1,002.80 0.52 +7.8% View
Q2 2024 942.60 0.44 +7.4% View